Russell, A <br/><br/>
Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada.  [electronic resource] 

 -  Clinical therapeutics  Nov 2001 
 - 1824-38; discussion 1791 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>0149-2918 
<br/><br/><label>Standard No.: </label>10.1016/s0149-2918(00)80079-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--drug therapy<br/>Canada<br/>Female<br/>Humans<br/>Infliximab<br/>Joint Deformities, Acquired--drug therapy<br/>Male<br/>Middle Aged